Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vanda Pharmaceuticals (VNDA) Gross Margin (2016 - 2025)

Vanda Pharmaceuticals (VNDA) has disclosed Gross Margin for 13 consecutive years, with 93.3% as the latest value for Q4 2025.

  • Quarterly Gross Margin fell 183.0% to 93.3% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 93.96% through Dec 2025, down 34.0% year-over-year, with the annual reading at 93.96% for FY2025, 34.0% down from the prior year.
  • Gross Margin hit 93.3% in Q4 2025 for Vanda Pharmaceuticals, down from 94.75% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 95.13% in Q4 2024 to a low of 90.3% in Q3 2021.
  • Historically, Gross Margin has averaged 92.29% across 5 years, with a median of 92.36% in 2023.
  • Biggest five-year swings in Gross Margin: skyrocketed 277bps in 2024 and later crashed -183bps in 2025.
  • Year by year, Gross Margin stood at 90.83% in 2021, then decreased by -1bps to 90.33% in 2022, then grew by 2bps to 92.36% in 2023, then rose by 3bps to 95.13% in 2024, then fell by -2bps to 93.3% in 2025.
  • Business Quant data shows Gross Margin for VNDA at 93.3% in Q4 2025, 94.75% in Q3 2025, and 94.8% in Q2 2025.